peoplePerson
Volker Heinemann
Gastrointestinal oncologist who led FIRE-3, a key trial of cetuximab versus bevacizumab in colorectal cancer.
Volker Heinemann directs the LMU comprehensive cancer centre and led the FIRE-3 trial in metastatic colorectal cancer, which shaped anti-EGFR use by tumour sidedness.
Role
Director, Comprehensive Cancer Center Munich (LMU); Professor of Medical Oncology
Institution
Specialisms
Colorectal cancerPancreatic cancerAnti-EGFR therapy
Profiles
| Title | Journal | Year |
|---|---|---|
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3) | Lancet Oncology | 2014 |
Pages like this
not linked directly; found by shared links- PairingAnti-EGFR antibody + chemotherapy in left-sided RAS/BRAF wild-type mCRC
Shares CRYSTAL & FIRE-3, Cetuximab, Colorectal cancer.
- PersonCarsten Bokemeyer
Shares Cetuximab, Colorectal cancer.
- PersonDongsheng Tu
Shares Cetuximab, Colorectal cancer.
- ProductFOLFIRI (5-FU, leucovorin, irinotecan)
Shares CRYSTAL & FIRE-3, Colorectal cancer.
- InstitutionTUM Klinikum rechts der Isar / CCC München
Shares LMU Klinikum München, Pancreatic ductal adenocarcinoma, Colorectal cancer.
- TermSidedness (left vs right colon)
Shares CRYSTAL & FIRE-3, Colorectal cancer.
- TrialSUNLIGHT
Shares Bevacizumab, Colorectal cancer.
- PersonRyan B. Corcoran
Shares Cetuximab, Colorectal cancer.